[HTML][HTML] An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment

T Grafone, M Palmisano, C Nicci, S Storti - Oncology reviews, 2012 - ncbi.nlm.nih.gov
Hematopoiesis, the process by which the hematopoietic stem cells and progenitors
differentiate into blood cells of various lineages, involves complex interactions of …

FLT3: ITDoes matter in leukemia

M Levis, D Small - Leukemia, 2003 - nature.com
Abstract FMS-like tyrosine kinase-3 (FLT3), a receptor tyrosine kinase, is important for the
development of the hematopoietic and immune systems. Activating mutations of FLT3 are …

Flt3 Ligand Regulates Dendritic Cell Development from Flt3+ Lymphoid and Myeloid-committed Progenitors to Flt3+ Dendritic Cells In Vivo

H Karsunky, M Merad, A Cozzio, IL Weissman… - The Journal of …, 2003 - rupress.org
Stimulation of Flt3 receptor tyrosine kinase through its cognate ligand expands early
hematopoietic progenitor and dendritic cells (DCs) in humans and mice. The exact …

Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways

M Mizuki, R Fenski, H Halfter… - Blood, The Journal …, 2000 - ashpublications.org
Somatic mutations of the receptor tyrosine kinase Flt3 consisting of internal tandem
duplications (ITD) occur in 20% of patients with acute myeloid leukemia. They are …

[HTML][HTML] Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

FG Rücker, L Du, TJ Luck, A Benner, J Krzykalla… - Leukemia, 2022 - nature.com
In acute myeloid leukemia (AML) internal tandem duplications of the FLT3 gene (FLT3-ITD)
are associated with poor prognosis. Retrospectively, we investigated the prognostic and …

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

M Levis, J Allebach, KF Tse, R Zheng… - Blood, The Journal …, 2002 - ashpublications.org
Constitutively activating internal tandem duplication (ITD) and point mutations of the receptor
tyrosine kinase FLT3 are present in up to 41% of patients with acute myeloid leukemia …

[HTML][HTML] Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia

MT Gebru, HG Wang - Journal of Hematology & Oncology, 2020 - Springer
Acute myeloid leukemia (AML) is a heterogeneous disease caused by several gene
mutations and cytogenetic abnormalities affecting differentiation and proliferation of myeloid …

Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival

Y Kikushige, G Yoshimoto, T Miyamoto… - The Journal of …, 2008 - journals.aai.org
Abstract FLT3/FLK2, a member of the receptor tyrosine kinase family, plays a critical role in
maintenance of hematopoietic homeostasis, and the constitutively active form of the FLT3 …

In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects

M Levis, R Pham, BD Smith, D Small - Blood, 2004 - ashpublications.org
Patients with acute myeloid leukemia (AML) harboring internal tandem duplication mutations
of the FLT3 receptor (FLT3/ITD mutations) have a poor prognosis compared to patients …

Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation

KF Tse, G Mukherjee, D Small - Leukemia, 2000 - nature.com
Aberrant expression of FLT3 has been found in most cases of B-lineage ALL and AML, and
subsets of T cell ALL, CML in blast crisis and CLL. In 20% of patients with AML the receptor …